Chardan Capital Reiterates “Buy” Rating for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Chardan Capital restated their buy rating on shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR – Free Report) in a research note issued to investors on Wednesday morning, Benzinga reports. The firm currently has a $60.00 price objective on the biotechnology company’s stock. ARWR has been the subject of a number of other reports. Cantor Fitzgerald reaffirmed an […]
More Stories
Compound Dai Reaches One Day Trading Volume of $428.91 (CDAI)
Compound Dai (CDAI) traded flat against the dollar during the 1-day period ending at 17:00 PM E.T. on July 5th....
Baby Doge Coin Price Down 16.3% Over Last 7 Days (BabyDoge)
Baby Doge Coin (BabyDoge) traded down 5.6% against the dollar during the 24-hour period ending at 17:00 PM ET on...
Unizen Self Reported Market Cap Reaches $57.91 Million (ZCX)
Unizen (ZCX) traded 4.5% lower against the dollar during the one day period ending at 17:00 PM ET on July...
Coq Inu 24-Hour Trading Volume Tops $9.61 Million (COQ)
Coq Inu (COQ) traded up 8.7% against the U.S. dollar during the 24 hour period ending at 17:00 PM Eastern...
Holo (HOT) Achieves Market Cap of $252.52 Million
Holo (HOT) traded down 5.8% against the U.S. dollar during the 1 day period ending at 17:00 PM E.T. on...
Wrapped eETH (WEETH) Trading 11.8% Lower This Week
Wrapped eETH (WEETH) traded 5.6% lower against the dollar during the 24 hour period ending at 17:00 PM E.T. on...